Skip to content
(Bloomberg) -- Wells Fargo & Co. plummeted after reporting its first quarterly loss since 2008 as loan-loss provisions soared with the bank expecting a more severe downturn from the coronavirus pandemic.The firm set aside a record $9.5 billion for credit losses, about $4 billion more than analysts had expected. Wells Fargo executives had warned they would earmark more for soured loans than the first quarter’s $4 billion as the pandemic continues to rage throughout the U.S. and weigh on companies and workers.The San Francisco-based lender also cut its dividend to 10 cents a share from 51 cents. Wells Fargo said last month it would lower the payout after the Federal Reserve implemented a new rule tying dividends to earnings. The bank’s $2.4 billion loss in the second quarter was a stark turnaround from the near-record $6.2 billion in profit it posted a year ago.“We are extremely disappointed in both our second-quarter...
The San Francisco-based bank also cut its dividend for the third quarter to 10 cents per share from 51 cents previously to reflect the U.S. Federal Reserve's recent curbs on bank dividends. Net interest income fell 18% from the prior period, as interest rates have fallen to near zero....
Shares in IMV Inc. (IMV) are spiking 134% in Tuesday’s pre-market trading after the clinical-stage biopharma company said it made “rapid progress” in developing its candidate vaccine to prevent COVID-19 infection.The stock surged to $4 in pre-market trading as IMV said that it was working closely with regulatory agencies and its partners to initiate clinical studies as quickly as possible. The plan for the Phase 1 clinical study, agreed with Health Canada, is a randomized controlled study, assessing the safety and immunogenicity of its vaccine candidate DPX-COVID-19, to be conducted in 84 healthy adults across two age cohorts.DPX-COVID-19, is based on the Canadian biotech’s first-in-class lipid-based vaccine delivery platform that generates targeted and sustained immune response in vivo. Fully synthetic, the vaccine candidate is designed to focus the immune response on the weaknesses of the virus with the goal to optimize safety and efficacy.“The rapid progress in target selection, the vaccine...
